Plasmalyte A

Summary

Plasmalyte A (CHEMBL4650416) is a phase-3 clinical-stage unknown; indicated across 5 conditions including injury and adult acute respiratory distress syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650416
Name	Plasmalyte A
Type	Unknown
Max phase	3

Also known as: Plasma-lyte a, Plasmalyte a, PLASMALYTE A

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
injury	2	MONDO:0021178	EFO:0000546
adult acute respiratory distress syndrome	2	MONDO:0100130	MONDO:0100130
anterolateral myocardial infarction	2	MONDO:0006652	EFO:1000812
ischemic disease	1	MONDO:0005053	EFO:0000556
myocardial infarction	1	MONDO:0005068	EFO:0000612

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1/PHASE2	2
PHASE2	2
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03115060	PHASE4	UNKNOWN	Comparison of Plasmalyte A, Normal Saline and Ringer Lactate as Intraoperative Fluid During Renal Transplantation
NCT03043131	PHASE3	UNKNOWN	Comparative Analysis Between Ringer’s Lactate vs Plasma Lyte-A as Cardiopulmonary Bypass Prime
NCT05253209	PHASE3	TERMINATED	A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
NCT00936819	PHASE2	ACTIVE_NOT_RECRUITING	The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial
NCT00883727	PHASE1/PHASE2	COMPLETED	Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI
NCT00883870	PHASE1/PHASE2	COMPLETED	Mesenchymal Stem Cells in Critical Limb Ischemia
NCT02097641	PHASE2	COMPLETED	Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
NCT01270854	Not specified	COMPLETED	Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).